🏛️ Verified NIH Record • Updated 2026-07-10
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) (NCT05248646)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
🩺 Plain-English Summary (8th-Grade Level)
To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham - Site #336 — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (308 Sites)
Showing the first 25 of 308 sites.
- University of Alabama at Birmingham - Site #336 — Birmingham, Alabama
- Mayo Clinic Arizona - Site #363 — Phoenix, Arizona
- University of Arkansas for Medical Sciences - Site #353 — Little Rock, Arkansas
- Amicis Research Center - Site #341 — Granada Hills, California
- University of CA San Diego - Site #351 — La Jolla, California
- California Institute of Renal Research - Site #371 — La Mesa, California
- Loma Linda University Health Care Clinical Trial Center Clinic - Site #372 — Loma Linda, California
- Academic Medical Research Institute - Site #333 — Los Angeles, California
- Kaiser Permanente - Southern California Permanente Medical Group SCPMG - LAMC - Site #325 — Los Angeles, California
- Stanford University - Site #370 — Palo Alto, California
- North America Research Institute - Site #335 — San Dimas, California
- University of California, San Francisco - Site #377 — San Francisco, California
- Colorado Kidney Care PC - Site #330 — Denver, Colorado
- Mayo Clinic in Florida - Site #321 — Jacksonville, Florida
- South Florida Research Institute - Site #323 — Lauderdale Lakes, Florida
- Columbus Research Group - Site #376 — South Miami, Florida
- Fides Clinical Research North Atlanta Kidney Specialists - Site #373 — Atlanta, Georgia
- Georgia Nephrology - Site #356 — Lawrenceville, Georgia
- University of Iowa Hospitals & Clinics - Site #359 — Iowa City, Iowa
- Kansas Nephrology Associates - Site #322 — Wichita, Kansas
- Ochsner Medical Center - Site #334 — New Orleans, Louisiana
- University of Maryland - Site #355 — Baltimore, Maryland
- MGH Harvard - Site #369 — Boston, Massachusetts
- Brigham and Women's Hospital, Division of Renal Medicine - Site #379 — Boston, Massachusetts
- Tufts Medical Center - Site #349 — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Immunoglobulin A Nephropathy
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Alabaster, Alabama
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Huntsville, Alabama
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy — Birmingham, Alabama
- A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US — Boston, Massachusetts
Explore by condition: All Immunoglobulin A Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.